Dyslipidaemia in juvenile dermatomyositis: the role of disease activity

Nenhuma Miniatura disponível
Citações na Scopus
21
Tipo de produção
article
Data de publicação
2013
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
CLINICAL & EXPER RHEUMATOLOGY
Autores
Citação
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, v.31, n.4, p.638-644, 2013
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective To evaluate the presence of dyslipidaemia in JDM and its possible risk factors. Methods Twenty-five JDM patients were compared to 25 healthy controls according to demographic data, body composition, fasting lipoproteins, glycaemia, insulin, antibodies and muscle enzymes. JDM scores were assessed: CMAS, MMT, DAS, MYOACT and MYTAX. Results Abnormal lipid profile was found in nine patients and four controls (36% vs. 16%, p=0.196). TDM patients demonstrated significant higher levels of triglycerides (TG) [80(31-340) vs. 61(19-182) mgldL, p=0.011 j and higher frequency of abnormal levels of high density lipoproteins (HDL) (28% vs. 4%, p=0.04) when compared to controls. JDM patients with dyslipidaemia demonstrated significant lower median of HDL levels 129(0-49) vs. 50(39-72) mgldL, p=0.0005, higher frequency of low HDL levels (77% vs. 0%, p=0.0001),.higher TG levels [128(31-340) vs. 69(46-138) mgldL, p=0.011), and also a higher frequency of increased levels of TG (44% vs. 0%, p=0.01), and TC (33% vs. 0%, p=0.03) when compared to those without this condition. Positive anti-LPL antibody was detected in just one JDM patient with abnormal lipid profile. JDM with dyslipidaemia had higher ESR (26 vs. I 4.5mmllsthour, p=0.006), CRP (2.1 vs. 0.4mgldL, p=0.01), DAS (6 vs. 2, p=0.008), MYOACT(0.13 vs. 0.01, p=0.012), MYTAX(0.06vs.0,p=0.018), and lower scores of CMAS (47 vs. 52, p=0.024) and MMT (78 vs. 80, p=0.001) compared to JDM without dyslipidaemia. Positive correlations were detected between TG levels and CRP (7-.19.697, p=0.001), DAS (r-0.610, p=0.001), MYOACT (r=0.661, p=0.001),114YTAX (r-0.511, p=0.008), and negative correlations with CMAS (r=-0.506, p=0.009) and MMT (r=-0.535, p=0.005). No differences were found between these groups regarding body composition, lipodystrophy, anti-LPL antibodies, and treatment except by higher frequency of cyclosporine current use in patients with dys.lipidaemia (33% vs. 0%, p=0.03). Conclusions Dyslipidaemia in JDM patients was characterised by increased levels of TG and low levels of HDL. Disease activity and cyclosporine use were the mainly factors associated to these abnormalities.
Palavras-chave
dyslipidaemia, juvenile dermatomyositis, autoantibody, eyelosporine, disease activity
URI
https://observatorio.fm.usp.br/handle/OPI/5064
Referências
  1. Ardoin SP, 2010, LUPUS, V19, P1315, DOI 10.1177/0961203310373937
  2. BALLANTYNE CM, 1989, JAMA-J AM MED ASSOC, V262, P53, DOI 10.1001/jama.262.1.53
  3. Bingham A, 2008, MEDICINE, V87, P70, DOI 10.1097/MD.0b013e31816bc604
  4. Bode RK, 2003, ARTHRIT RHEUM-ARTHR, V49, P7, DOI 10.1002/art.10924
  5. BOHAN A, 1975, NEW ENGL J MED, V292, P344, DOI 10.1056/NEJM197502132920706
  6. Borba EF, 2001, J RHEUMATOL, V28, P780
  7. Borba EF, 2006, CLIN DEV IMMUNOL, V13, P203, DOI 10.1080/17402520600876945
  8. Carreau V, 2011, PEDIATR DRUGS, V13, P267, DOI 10.2165/11591650-000000000-00000
  9. Coyle Kathleen, 2009, J Pediatr, V155, P882, DOI 10.1016/j.jpeds.2009.06.009
  10. de Carvalho JF, 2004, ARTHRITIS RHEUM, V50, P3610, DOI 10.1002/art.20630
  11. Eimer MJ, 2011, J PEDIATR-US, V159, P795, DOI 10.1016/j.jpeds.2011.05.015
  12. FOSSATI P, 1982, CLIN CHEM, V28, P2077
  13. FRIEDEWA.WT, 1972, CLIN CHEM, V18, P499
  14. Hayata ALS, 2005, LUPUS, V14, P613, DOI 10.1191/0961203305lu2177oa
  15. Huemer C, 2001, J RHEUMATOL, V28, P610
  16. KROLL M, 1986, J RHEUMATOL, V13, P349
  17. Lovell DJ, 1999, ARTHRITIS RHEUM, V42, P2213, DOI 10.1002/1529-0131(199910)42:10<2213::AID-ANR25>3.0.CO;2-8
  18. Marangoni RG, 2011, CLINICS, V66, P1549, DOI 10.1590/S1807-59322011000900007
  19. Marcen R, 2006, TRANSPLANT P, V38, P2427, DOI 10.1016/j.transproceed.2006.08.070
  20. Miller LW, 2002, AM J TRANSPLANT, V2, P807, DOI 10.1034/j.1600-6143.2002.20902.x
  21. Omori CH, 2012, ARTHRIT CARE RES, V64, P1186, DOI 10.1002/acr.21684
  22. PEREIRA A, 2005, ARQ BRAS CARDIOL, V8, P4
  23. Posadas-Romero C, 2004, ARTHRITIS RHEUM, V50, P160, DOI 10.1002/art.11472
  24. PRADO R, 2006, CLIN EXP RHEUMATOL, V24, P594
  25. Sallum AME, 2002, ARQ NEURO-PSIQUIAT, V60, P889, DOI 10.1590/S0004-282X2002000600001
  26. Sarkissian T, 2006, ARTHRITIS RHEUM, V54, P1283, DOI 10.1002/art.21748
  27. Sato JO, 2009, CLIN EXP RHEUMATOL, V27, P1031
  28. Schanberg LE, 2012, ARTHRITIS RHEUM-US, V64, P285, DOI 10.1002/art.30645
  29. SIEDEL J, 1983, CLIN CHEM, V29, P1075
  30. Sultan SM, 2008, ARTHRITIS RHEUM, V58, P3593, DOI 10.1002/art.23963
  31. Targoff Ira N, 2002, Curr Rheumatol Rep, V4, P434, DOI 10.1007/s11926-002-0089-7
  32. Verma S, 2006, ARTHRIT RHEUM-ARTHR, V55, P564, DOI 10.1002/art.22108
  33. WARNICK GR, 1979, CLIN CHEM, V25, P596
  34. Zanette CD, 2010, REV BRAS REUMATOL, V50, P190, DOI 10.1590/S0482-50042010000200008

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/ICr
Artigos e Materiais de Revistas Científicas - LIM/17
Artigos e Materiais de Revistas Científicas - LIM/36